Relay Therapeutics Stock Return On Equity
| RLAY Stock | USD 4.80 0.04 0.84% |
Relay Therapeutics fundamentals help investors to digest information that contributes to Relay Therapeutics' financial success or failures. It also enables traders to predict the movement of Relay Stock. The fundamental analysis module provides a way to measure Relay Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Relay Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | (0.45) | (0.43) |
Relay | Return On Equity |
Relay Therapeutics Company Return On Equity Analysis
Relay Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Relay Therapeutics Return On Equity | -0.43 |
Most of Relay Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relay Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Relay Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Relay Therapeutics is extremely important. It helps to project a fair market value of Relay Stock properly, considering its historical fundamentals such as Return On Equity. Since Relay Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Relay Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Relay Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Relay Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Relay Therapeutics has a Return On Equity of -0.4269. This is 98.22% lower than that of the Biotechnology sector and 98.83% lower than that of the Health Care industry. The return on equity for all United States stocks is 37.71% higher than that of the company.
Relay Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relay Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics of similar companies.Relay Therapeutics is currently under evaluation in return on equity category among its peers.
Relay Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Relay Therapeutics from analyzing Relay Therapeutics' financial statements. These drivers represent accounts that assess Relay Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Relay Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 150.1M | 1.8B | 2.9B | 1.7B | 1.3B | 1.1B | |
| Enterprise Value | 132.9M | 1.3B | 2.0B | 735.6M | 1.3B | 683.8M |
Relay Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Relay Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Relay Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Relay Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (39.47) % | ||||
| Current Valuation | 6.95 M | ||||
| Shares Outstanding | 167.38 M | ||||
| Shares Owned By Insiders | 1.71 % | ||||
| Shares Owned By Institutions | 98.10 % | ||||
| Number Of Shares Shorted | 11.61 M | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 80.30 X | ||||
| Revenue | 25.55 M | ||||
| Gross Profit | 1.38 M | ||||
| EBITDA | (374.15 M) | ||||
| Net Income | (341.97 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 8.72 X | ||||
| Total Debt | 53.47 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 5.03 X | ||||
| Cash Flow From Operations | (300.32 M) | ||||
| Short Ratio | 9.06 X | ||||
| Earnings Per Share | (2.63) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 21.91 | ||||
| Number Of Employees | 294 | ||||
| Beta | 1.68 | ||||
| Market Capitalization | 803.44 M | ||||
| Total Asset | 843.98 M | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 739.83 M | ||||
| Net Asset | 843.98 M |
About Relay Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relay Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.